Federal Register / Vol. 89, No. 32 / Thursday, February 15, 2024 / Notices 11845 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID New Innovators 

Awards (DP2 Clinical Trial Not Allowed). 

Date: March 11–13, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Rockville, MD 

20852 (Video Assisted Meeting). 

Contact Person: Vanitha Sundaresa Raman, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, MSC 9834, Rockville, MD 

20852, 301–761–7949, vanitha.raman@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: February 12, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–03195 Filed 2–14–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information may be obtained 

by communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852 by contacting 

Dawn Taylor-Mulneix at 301–451–8021 

or dawn.taylor-mulneix@nih.gov. A 

signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Equipping Natural Killer Cells With a 

CD28H-Containing Chimeric Antigen 

Receptor To Overcome Inhibition for 

Cancer Immunotherapy 

Description of Technology 

Immunotherapy with chimeric 

antigen receptor (CAR) cytotoxic T cells 

have been successful in the clinical 

treatment of hematologic cancers; 

however adverse side effects such as 

severe cytokine release syndrome and 

neurotoxicity are associated with CAR– 

T cell infusion. CAR natural killer (NK) 

cells represent a viable alternative with 

demonstrated advantages over CAR–T 

cells for the elimination of tumor cells, 

but NK inhibitory cell receptors need to 

be reduced or overridden. To overcome 

this challenge, scientists at NIAID have 

developed CAR constructs that 

overcome inhibition of NK cells by 

receptors for human major 

histocompatibility complex molecules 

HLA–E and HLA–C, based on in vitro 

studies. NK cells that are expressing 

variants of this invention robustly 

overcome inhibition imposed by CD19+

HLA–I+ tumor cells and are cytotoxic to 

them. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• Method of adoptive cell therapy 

where CAR–NK cells are the effective 

cell. 

Competitive Advantages 

• CD28H CAR–NK cells induce a 

more robust anti-tumor cytotoxic 

activity compared to third generation 

CAR–T cells and are more potent in 

overcoming inhibition. 

• CAR–NK can be developed without 

the need of genetic silencing of TCR. 

Developmental Stage 

• Pre-clinical. 

Inventors: Eric Long, Ph.D. and 

Xiaoxuan Zhuang, both of NIAID. 

Publications: 

Zhuang X., Long E.O., ‘‘NK cells 

equipped with a chimeric antigen 

receptor that overcomes inhibition by 

HLA Class I for adoptive transfer of 

CAR–NK Cells. Front. Immunol. 

13:840844. https://www.frontiersin.org/ 

articles/10.3389/fimmu.2022.840844/ 

full. May 2, 2022. 

Zhuang X. and Long E.O., ‘‘CD28 

homolog is a strong activator of Natural 

Killer cells for lysis of B7H7-positive 

tumor cells.’’ Cancer Immunol. Res. 

7(6):939–951. https://cancerimmunol

res.aacrjournals.org/content/7/6/ 

939.long. April 24, 2019. 

Zhuang X, Long E.O. ‘‘Inhibitionresistant CARs for NK cell cancer 

immunotherapy.’’ Trends Immunol. 

40(12):1078–1081.https://www.science

direct.com/science/article/pii/

S1471490619302133?via%3Dihub. 

November 12, 2019. 

Intellectual Property: HHS Reference 

No. E–097–2020; Patent Application 

Nos.: PCT Application No. PCT/ 

US2020/02498, US: 17/914,027, 

Australia: 2020437669, Brazil: 

BR112022017512–4, Canada: 3174779, 

Europe: 20719313.7, India: 

2022170585054, Japan: 2022–557764, 

South Korea: 10–2022–7037236. 

Licensing Contact: To license this 

technology, please contact Dawn TaylorMulneix at 301–451–8021 or 

dawn.taylor-mulneix@nih.gov, and 

reference E–097–2020. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. For 

collaboration opportunities, please 

contact Dawn Taylor-Mulneix at 301– 

451–8021 or dawn.taylor-mulneix@

nih.gov. 

Dated: February 9, 2024. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2024–03121 Filed 2–14–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director; Notice of Charter 

Renewal 

In accordance with Title 41 of the 

U.S. Code of Federal Regulations, 

Section 102–3.65(a), notice is hereby 

given that the charter for the Cures 

Acceleration Network Review Board, 

was renewed for an additional two-year 

period on February 7, 2024. 


khammond on DSKJM1Z7X2PROD with NOTICES
11846 Federal Register / Vol. 89, No. 32 / Thursday, February 15, 2024 / Notices 

It is determined that the Cures 

Acceleration Network Review Board, is 

in the public interest in connection with 

the performance of duties imposed on 

the National Institutes of Health by law, 

and that these duties can best be 

performed through the advice and 

counsel of this group. 

Inquiries may be directed to Claire 

Harris, Director, Office of Federal 

Advisory Committee Policy, Office of 

the Director, National Institutes of 

Health, 6701 Democracy Boulevard, 

Suite 1000, Bethesda, Maryland 20892 

(Mail code 4875), Telephone (301) 496– 

2123, or harriscl@mail.nih.gov. 

Dated: February 9, 2024. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–03110 Filed 2–14–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director; Notice of Charter 

Renewal 

In accordance with Title 41 of the 

U.S. Code of Federal Regulations, 

Section 102–3.65(a), notice is hereby 

given that the charter for the National 

Center for Advancing Translational 

Sciences Advisory Council, was 

renewed for an additional two-year 

period on February 7, 2024. 

It is determined that the National 

Center for Advancing Translational 

Sciences Advisory Council, is in the 

public interest in connection with the 

performance of duties imposed on the 

National Institutes of Health by law, and 

that these duties can best be performed 

through the advice and counsel of this 

group. 

Inquiries may be directed to Claire 

Harris, Director, Office of Federal 

Advisory Committee Policy, Office of 

the Director, National Institutes of 

Health, 6701 Democracy Boulevard, 

Suite 1000, Bethesda, Maryland 20892 

(Mail code 4875), Telephone (301) 496– 

2123, or harriscl@mail.nih.gov. 

Dated: February 9, 2024. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–03104 Filed 2–14–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Daniel Lee at 301–761–6327 or 

daniel.lee5@nih.gov. Licensing 

information may be obtained by 

communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852; tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

DeePlexing—Extending Imaging 

Multiplexity Using Machine Learning 

Description of Technology: Spatial 

proteomics and transcriptomics are fastemerging fields with the potential to 

revolutionize various branches of 

biology. In the last five years, various 

multiplex immunofluorescence and 

immunohistochemistry imaging 

methods have been developed to stain 

5–60 different protein markers in a 

given tissue. Nonetheless, most of these 

techniques are iterative and can image 

a maximum of 3–8 markers in a single 

cycle, resulting in processing time of 

several hours to days. 

Scientists at National Institute of 

Allergy and Infectious Diseases (NIAID) 

and National Cancer Institute (NCI) have 

developed a new method— 

DeePlexing—that uses a deep learning 

algorithm to dramatically enhance the 

number of markers stained in a single 

imaging cycle. This is accomplished 

with no changes or upgrades to the 

imaging platform itself. In the 

DeePlexing method, multiple 

antibodies/probes are conjugated to the 

same fluorophores and later 

deconvolved computationally to retrieve 

the multichannel signal with high 

accuracy. In digital spatial profiling, 

DeePlexing enables the user to detect 

seven different protein markers in a 

single cycle using only three 

fluorophores and even quadruple the 

number of markers in a single round 

without compromising the quality of 

RNA and protein in the sample. For 

multiplex protein profiling, DeePlexing 

can potentially stain for up to 255 

different protein markets with eight 

fluorophores and deconvolve the signal 

for each of the 255 markers 

computationally. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404. 

Potential Commercial Applications: 

• Imaging platforms in spatial 

transcriptomics 

• Multiplex protein spatial imaging 

Competitive Advantages: 

• Enhances the number of markers 

stained in a single imaging cycle 

• Achieves this marker detection 

increase without compromising RNA 

or protein quality when that is part of 

the analytical pipeline 

• Reduces the required processing time 

for multiplex imaging platforms 

• Inexpensive and replicable 

Development Stage: 

• Prototype 

Inventors: Ronald N. Germain 

(NIAID), Spencer M. Grant (NIAID), 

Nishant Thakur (NIAID), Chen Zhao 

(NCI), and Abigail J. Wong-Rolle (NCI). 

Intellectual Property: HHS Reference 

No. E–202–2021–0; Software Tool. 

Licensing Contact: To license this 

technology, please contact Daniel Lee at 

301–761–6327 or daniel.lee5@nih.gov, 

and reference E–202–2021–0. 

Dated: February 9, 2024. 

Surekha Vathyam, 

Deputy Director,Technology Transfer and 

Intellectual Property Office,National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2024–03120 Filed 2–14–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Notice of Meeting for the 

Interdepartmental Serious Mental 

Illness Coordinating Committee 

(ISMICC) 

AGENCY: Substance Abuse and Mental 

Health Services Administration, 

Department of Health and Human 

Services. 


khammond on DSKJM1Z7X2PROD with NOTICES